Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer
Maneno muhimu
Kikemikali
Tarehe
Imethibitishwa Mwisho: | 12/31/2018 |
Iliyowasilishwa Kwanza: | 11/21/2016 |
Uandikishaji uliokadiriwa Uliwasilishwa: | 11/21/2016 |
Iliyotumwa Kwanza: | 11/24/2016 |
Sasisho la Mwisho Liliwasilishwa: | 01/28/2019 |
Sasisho la Mwisho Lilichapishwa: | 01/29/2019 |
Tarehe halisi ya kuanza kwa masomo: | 09/30/2016 |
Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 09/30/2020 |
Tarehe ya Kukamilisha Utafiti: | 01/31/2021 |
Hali au ugonjwa
Uingiliaji / matibabu
Device: imILT
Awamu
Vikundi vya Arm
Mkono | Uingiliaji / matibabu |
---|---|
Experimental: imILT Immunostimulating Interstitial Laser Thermotherapy (imILT) | Device: imILT |
Vigezo vya Kustahiki
Zama zinazostahiki Kujifunza | 18 Years Kwa 18 Years |
Jinsia Inastahiki Kujifunza | All |
Hupokea Wajitolea wa Afya | Ndio |
Vigezo | Inclusion Criteria: - Cytohistological diagnosis of ductal pancreatic adenocarcinoma . - Stage III disease (see above). - The patient is not a candidate for continued chemotherapy or (chemo)radiotherapy due to lack of demonstrable efficiency or to the side effects of the drugs. - Age between 18 and 80 years. - Anticipated compliance with treatment and follow-up. - Double informed consent for both imILT and possible surgery with radical intent (in the event of pre-operative overstaging). - At least a part of the tumor can be treated with imILT without damage to surrounding vital structures. - Have an ECOG performance status < 1 (l'Eastern Cooperative Oncology Group) Exclusion Criteria: - Not a candidate for laparotomy. - Becoming resectable after neoadjuvant chemotherapy. - Other simultaneous treatments for the same neoplasm. - Simultaneous other malignancies except for basal cell carcinoma. - HIV positive. - Active autoimmune disease. - Systemic corticosteroid medication. - Pregnancy or nursing. |
Matokeo
Hatua za Matokeo ya Msingi
1. Safety (adverse events) [36 months]
Hatua za Matokeo ya Sekondari
1. Inflammatory response in circulation measured by quantification of inflammatory cell populations [36 months]
2. Disease progression [36 months]
3. Evaluation of Quality of Life (using questionnaires) [36 months]
4. Usability of the device as evaluated by treatment logs [36 months]